转移性去势抵抗性前列腺癌的分子驱动因素：新的耐药途径。
Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance.
机构信息
a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
出版信息
Cancer Biol Ther. 2018;19(10):869-870. doi: 10.1080/15384047.2018.1449618. Epub 2018 May 14.
Abstract
Numerous growth-inducing signaling pathways have been implicated in the development of metastatic castrate-resistant prostate cancer, but their cross-talk with androgen receptor functions remains poorly understood. A recent study published in Science Signaling by Chen et al. has identified a novel androgen-mediated signaling axis driven by loss of SPDEF and gain of TGFBI to facilitate metastasis, which may explain the acquisition of resistance to androgen deprivation therapy. These findings suggest that therapeutic inhibition of androgen signaling may inadvertently promote castrate resistance by inhibiting tumor suppressive functions of the androgen receptor.
摘要
许多促进生长的信号通路被认为与转移性去势抵抗性前列腺癌的发生有关，但它们与雄激素受体功能的相互作用仍知之甚少。最近，Chen 等人在《科学信号》杂志上发表的一项研究确定了一条新的雄激素介导的信号轴，该信号轴由 SPDEF 的缺失和 TGFBI 的获得驱动，从而促进转移，这可能解释了对雄激素剥夺治疗的耐药性的获得。这些发现表明，雄激素信号的治疗性抑制可能通过抑制雄激素受体的肿瘤抑制功能而无意中促进去势抵抗。
相似文献
1
Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance.转移性去势抵抗性前列腺癌的分子驱动因素：新的耐药途径。
Cancer Biol Ther. 2018;19(10):869-870. doi: 10.1080/15384047.2018.1449618. Epub 2018 May 14.
2
Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.雄激素剥夺治疗后 SPDEF 的缺失和 TGFBI 活性的获得促进前列腺癌的 EMT 和骨转移。
Sci Signal. 2017 Aug 15;10(492):eaam6826. doi: 10.1126/scisignal.aam6826.
3
Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.雄激素剥夺疗法通过下调 SPDEF 并激活 CCL2 诱导前列腺癌细胞发生上皮-间充质转化。
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1717-1727. doi: 10.1016/j.bbadis.2018.02.016. Epub 2018 Mar 21.
4
Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.前列腺癌治疗反应中上皮-间质转化控制下的细胞死亡
Int J Urol. 2018 Apr;25(4):318-326. doi: 10.1111/iju.13505. Epub 2018 Jan 17.
5
Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.前列腺癌中的干细胞：解决去势抵抗难题及对激素治疗的意义
Cancer Biol Ther. 2006 Aug;5(8):901-6. doi: 10.4161/cbt.5.8.2949. Epub 2006 Aug 28.
6
Profiling Prostate Cancer Therapeutic Resistance.前列腺癌治疗抵抗的特征分析。
Int J Mol Sci. 2018 Mar 19;19(3):904. doi: 10.3390/ijms19030904.
7
ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.ETS1 转录活性在晚期前列腺癌中增加，并促进去势抵抗表型。
Carcinogenesis. 2012 Mar;33(3):572-80. doi: 10.1093/carcin/bgs007. Epub 2012 Jan 9.
8
TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.TCF7通过微小RNA-1介导的下调被雄激素受体抑制，并参与前列腺癌对雄激素剥夺的抗性发展。
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):172-178. doi: 10.1038/pcan.2017.2. Epub 2017 Feb 21.
9
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.Wnt/β-连环蛋白信号通路与前列腺癌治疗抵抗
Adv Exp Med Biol. 2019;1210:351-378. doi: 10.1007/978-3-030-32656-2_16.
10
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.雄激素剥夺诱导的 ZBTB46-PTGS1 信号促进前列腺癌的神经内分泌分化。
Cancer Lett. 2019 Jan;440-441:35-46. doi: 10.1016/j.canlet.2018.10.004. Epub 2018 Oct 9.
引用本文的文献
1
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.剖析雄激素剥夺疗法对晚期前列腺癌钙黏蛋白转换的影响：分子视角。
Oncol Res. 2023 Jan 12;30(3):137-155. doi: 10.32604/or.2022.026074. eCollection 2022.
2
Neuroplastinβ-mediated upregulation of solute carrier family 22 member 18 antisense (SLC22A18AS) plays a crucial role in the epithelial-mesenchymal transition, leading to lung cancer cells' enhanced motility.神经塑蛋白β介导的溶质载体家族22成员18反义基因（SLC22A18AS）上调在上皮-间质转化中起关键作用，导致肺癌细胞运动性增强。
Biochem Biophys Rep. 2020 May 17;22:100768. doi: 10.1016/j.bbrep.2020.100768. eCollection 2020 Jul.
本文引用的文献
1
Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.雄激素剥夺治疗后 SPDEF 的缺失和 TGFBI 活性的获得促进前列腺癌的 EMT 和骨转移。
Sci Signal. 2017 Aug 15;10(492):eaam6826. doi: 10.1126/scisignal.aam6826.
2
Epithelial-mesenchymal transition in prostate cancer: an overview.前列腺癌中的上皮-间质转化：概述
Oncotarget. 2017 May 23;8(21):35376-35389. doi: 10.18632/oncotarget.15686.
3
Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis.异常的转化生长因子-β信号通路在前列腺肿瘤发生的雄性小鼠模型中驱动去势抵抗性前列腺癌。
Endocrinology. 2017 Jun 1;158(6):1612-1622. doi: 10.1210/en.2017-00086.
4
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.去势抵抗性前列腺癌中的雄激素受体信号传导：坚持不懈的一课。
Endocr Relat Cancer. 2016 Dec;23(12):T179-T197. doi: 10.1530/ERC-16-0422. Epub 2016 Oct 31.
5
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌对新型抗雄激素疗法的耐药性
Clin Med Insights Oncol. 2016 Mar 16;10(Suppl 1):1-9. doi: 10.4137/CMO.S34534. eCollection 2016.
6
The transcription factor SPDEF suppresses prostate tumor metastasis.转录因子 SPDEF 抑制前列腺肿瘤转移。
J Biol Chem. 2012 Aug 24;287(35):29968-78. doi: 10.1074/jbc.M112.379396. Epub 2012 Jul 2.
7
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.雄激素剥夺导致前列腺中的上皮-间充质转化：对雄激素剥夺治疗的影响。
Cancer Res. 2012 Jan 15;72(2):527-36. doi: 10.1158/0008-5472.CAN-11-3004. Epub 2011 Nov 22.
8
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.靶向 N-钙黏蛋白的单克隆抗体抑制前列腺癌生长、转移和去势抵抗。
Nat Med. 2010 Dec;16(12):1414-20. doi: 10.1038/nm.2236. Epub 2010 Nov 7.
9
Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.雄激素和雄激素受体在前列腺癌细胞上皮间质转化和侵袭中的作用。
FASEB J. 2010 Mar;24(3):769-77. doi: 10.1096/fj.09-136994. Epub 2009 Nov 9.
10
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.间歇性雄激素抑制疗法治疗前列腺癌的潜在益处：文献系统评价。
Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7.
Zotero 插件